Article Figures & Data
Figures
- Figure 1
- The flowchart of literature inclusion.
- Figure 2
- Risk of bias summary of included studies.14-19
- Figure 3
- Forest plot of the effects of rivaroxaban on short-term all-cause mortality.
- Figure 4
- Forest plot of the effects of rivaroxaban on the major bleeding rate.
- Figure 5
- Forest plot of the effects of rivaroxaban on the overall bleeding rate.
- Figure 6
- Forest plot of the effects of rivaroxaban on the thrombotic events.
- Figure 7
- Forest plot of the effects of rivaroxaban on the hospitalization rates in outpatients.
Tables
Study Country Study design Disease severity Interventions and dosage Controls Primary outcome Follow up Lopes et al14 Brazil Multicentre open-label RCT COVID-19 patients hospitalized with symptoms for up to 14 days Rivaroxaban 20mg OD for 30 days or a reduced dose of 15 mg/day with a creatinine clearance of 30-49 mL/min or enoxaparin or intravenous UFH for patients with an unstable condition, followed by rivaroxaban for 30 days (n=311) Enoxaparin or unfractionated heparin (n=304) CrCl ≥30: enoxaparin 40 mg SC every 24 hours or UFH 5000 units SC every 8-12 hours if BMI is <40; enoxaparin 60 mg SC every 24 hours or 40 mg SC every 12 hours or UFH 7500 units SC every 8-12 hours if BMI is ≥40; CrCl <30: UFH 5000 units SC every 8-12 hours if BMI <40; UFH 7500 units SC every 8-12 hours if BMI is ≥40. Time to death, length of hospital stay and number of days on oxygen support 30 days Ananworanich et al15 USA Single center RCT Patients with mild COVID-19 and high risk for severe COVID-19 Rivaroxaban 10mg OD for 21days (n=84) Multivitamin one tablet OD for 21 days (n=82) Serious AEs, hypersensitivity, major bleeding events, the frequency of AEs 35 days Ramacciott et al16 USA Multicentre open-label RCT patients at discharge who were hospitalized with COVID-19 for a minimum of 3 days Rivaroxaban 10mg OD (n=159) Placebo (n=159) Venous thromboembolism with symptomatic or fatal, asymptomatic symptomatic arterial thromboembolism, and cardiovascular death 35days Avezum et al19 Brazil Multicentre open-label RCT Patients with mild or moderate COVID-19, within ≤7 days from symptom onset Rivaroxaban 10 mg OD for 14 days (n=327) Routine care (n=330) Thromboembolic events rate of ventilation and hospitalization, mortality 30 days Piazza et al18 USA Multicentre double-blind RCT Patients with COVID-19, at least one thrombosis risk factor Rivaroxaban 10 mg OD for 35 days (n=599) Placebo (n=598) Thromboembolic events, all-cause hospitalization, all-cause mortality up to day 35 35 days Rauch‑Kröhnert et al17 Germany Multicentre open-label RCT Ambulatory or hospitalized adults with moderate to severe COVID-19 Rivaroxaban 20mg OD for at least 7 days and followed with 10 mg OD for 28 days (n=43) heparin for at least 7 days followed by no thromboprophylaxis (n=45) The D-dimer level, the WHO 7-category ordinal scale at 7 days 35 days RCT: randomized controlled trial, COVID: coronavirus disease, OD: once daily, UFH: unfractionated heparin, CrCl: creatinine clearance, SC: subcutaneous, BMI: body mass index, AEs: adverse events, WHO: World Health Organization
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.